Skip to main content
. Author manuscript; available in PMC: 2015 Mar 1.
Published in final edited form as: Drug Dev Ind Pharm. 2013 Apr 19;40(3):370–379. doi: 10.3109/03639045.2012.763137

Figure 4.

Figure 4

Permeation profile of FITC-BSA through mouse skin from nanoemulsions (formulation B2) containing different concentrations of FITC-BSA and their corresponding control solutions containing FITC-BSA. Data represent mean ± SEM. Statistically significant differences in steady-state flux (p<0.05): 0.5 mg/mL nanoemulsion versus 2.5 mg/mL nanoemulsion and 4.0 nanoemulsion, 2.5 mg/mL nanoemulsion versus 2.5 mg/mL control, 4.0 mg/mL nanoemulsion versus 4.0 mg/mL control.